Systemic chemotherapy for the treatment of mycosis fungoides and Sézary syndrome

Dermatologic Therapy

Volumn 16, Issue 4, 2003, Pages 355-361

  Kuzel, Timothy M ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anti neoplastic therapy; Chemotherapy; Cytotoxic drugs; Mycosis fungoides

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC ANTIBIOTIC; BLEOMYCIN; CAMPTOTHECIN; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; DEPSIPEPTIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE PHOSPHATE; FLUOROURACIL; FOLINATE CALCIUM; FR 901228; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMIDAZOLE DERIVATIVE; INTERLEUKIN 12; INTERLEUKIN DERIVATIVE; METHOTREXATE; PENTOSTATIN; PREDNISOLONE; PSORALEN; TEMOZOLOMIDE; TETRAZINE DERIVATIVE; VIDARABINE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ALOPECIA; ATYPICAL MYCOBACTERIOSIS; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL TRIAL; CONFUSION; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DEMYELINATING DISEASE; DISEASE COURSE; DRUG USE; FUNGEMIA; GENERAL PRACTITIONER; HEALTH SURVEY; HISTORY OF MEDICINE; HUMAN; IMMUNE SYSTEM; MOTOR DYSFUNCTION; MOTOR WEAKNESS; MUCOSA INFLAMMATION; MYCOSIS FUNGOIDES; NAUSEA; PALLIATIVE THERAPY; PNEUMOCYSTIS PNEUMONIA; PUVA; RANDOMIZATION; REVIEW; SEZARY SYNDROME; SIDE EFFECT; SKIN ULCER; THROMBOCYTOPENIA; TOXOPLASMOSIS; ULTRAVIOLET A RADIATION; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SEZARY SYNDROME; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0346729962     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1396-0296.2003.01648.x     Document Type: Review

References (35)

1. Levi JA, Wiernik PH. Management of mycosis fungoides: current status and future prospects. Medicine 1974: 54: 73-98.
2. Holmes RC, McGibbon DH, Black MM. Mycosis fungoides: progression towards Sezary syndrome reversed with chlorambucil. Clin Exp Dermatol 1983: 8: 429-435.
3. Wiman G, Cadman E, Braverman I. Cisplatin treatment of cutaneous T-cell lymphoma. [Letter.] Cancer Treat Rep 1981: 65: 920.
4. Molin L, Thomsen K, Volden G, et al. Epipodophylotoxin (VP-16-23) in mycosis Fungoides: a report for the Scandinavian Mycosis Fungoides Study Group. Acta Derm Venereol 1979: 59: 84-89.
5. McDonald CJ, Bertino JR. Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor. Cancer Treat Rep 1978: 62: 1009-1014.
6. Schappell DL, Alper JC, McDonald CJ. Treatment of advanced mycosis fungoides and Sezary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue. Arch Dermatol 1995: 131: 307-317.
7. Saven A, Piro LW. The newer purine analogs. Cancer 1993: 72: 3470-3483.
8. Cummings FJ, Kim K, Neiman RS, et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 1991: 9: 565-571.
9. Grever MR, Bisacciaa E, Scarborough DA, et al. An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 1983: 61: 279-282.
10. Dearden C, Matutes E, Catovsky D. Deoxycoformycin in the treatment of mature T-cell leukemias. Br J Cancer 1991: 64: 903-906.
11. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1999: 17: 3117-3121.
12. Von Hoff D, Dahlberg S, Hartstock R, Eyre HJ. Activity of fludarabine monophosphate in patients with advance mycosis fungoides/Sezary syndrome. J Natl Cancer Inst 1990: 82: 1353-1355.
13. Kuzel TM, Huria A, Samuelson E, et al. Phase II trial of 2-chlorodeoyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 1996: 87: 906-911.
14. Saven A, Carrera CJ, Carson DA, et al. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992: 80: 587-592.
15. O'Brien S, Kurzrock R, Duvic M, et al. 2-Chloroxdeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 1994: 84: 733-737.
16. Betticher DC, Fey MF, von Rohr A, et al. High incidence of infections after 2-chlorodeoxyadenosine therapy in patients with malignant lymhomas and chronic and acute leukemias. Ann Oncol 1994: 5: 57-61.
17. Winkelman RK, Buechner SA, Diaz-Perez JL. Pre Sezary syndrome. J Am Acad Dermatol 1984: 10: 992-998.
18. Grozea PN, Jones SE, McKelvey EM, et al. Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group Study. Cancer Treat Rep 1979: 63: 647-649.
19. Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999: 86: 1368-1376.
20. Sausville EA, Worsham GF, Matthews MJ, et al. Histopathologic assessment of lymph nodes in mycosis Fungoides/Sezary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum Pathol 1985: 16: 1098-1109.
21. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989: 321: 1784-1790.
22. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000: 18: 2603-2606.
23. Wilson WH, Little R, Pearson D, et al. Phase II and dose-escalation with or without granulotyce colony-stimulating factor study of 9-aminocampothecin in relapsed and refractory lymphomas. J Clin Oncol 1998: 16: 2345-2351.
24. Argiris A, Heald P, Kuzel T, et al. Phase II trial of 9-aminocampothecin as a 72-hour infusion in cutaneous T-cell lymphoma. Invest New Drugs 2001: 19: 321-326.
25. Wollina U, Graefe T, Karte K. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 2000: 42: 40-46.
26. 6-alkylguanine-DNA alkyltransferase. Prog Nucl Acid Res Mol Biol 1995: 51: 167-223.
27. Ludlum DB. The chloroethylnitrosureas: sensitivity and resistance to cancer chemotherapy at the molecular level. Cancer Invest 1997: 15: 588-598.
28. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosureas: a Southwest Oncology Group Study. J Clin Oncol 1998: 16: 3310-3315.
29. 6-alkylguanine-DNA Alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clin Cancer Res 1999: 5: 2059-2064.
30. Rosen ST, Guitart J, Martone B, et al. Phase II trial of temozolomide for treatment of mycosis fungoides/Sezary syndrome. [Abstract 1140.] Proc ASCO 2002: 21: 286a.
31. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001: 98: 2865-2868.
32. Piekarz R, Robey R, Fojo T, et al. Analysis of molecular markers and targets in trials of depsipeptide, FR901228, a histone deacetylase inhibitor with clinical activity in T-cell lymphoma. [Abstract 88.] Proc ASCO 2002: 21: 23a.
33. Sterling JC, Marcus R, Burrows NP, Roberts SO. Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation. Clin Exp Dermatol 1995: 20: 73-77.
34. Koppel MC, Stoppa AM, Resbeut M, et al. Mycosis fungoides and allogeneic bone marrow transplantation. Acta Derm Venereol (Stockh) 1994: 74: 331-334.
35. Burt RK, Kuzel TM, Fishman M, et al. Stem cell component therapy: supplementation of unmanipulated marrow with CD34 enriched peripheral blood stem cells. Bone Marrow Transplantation 1999: 23: 381-386.